Long Pharmaron/Short Wuxi: Take Profit Now, A-Share Pullback the Key Risk
Pharmaron, the second-largest contract research organization (CRO) in China, was listed in Hong Kong on November 28th. The deal was anchored by a...
448 Views
WuXi Biologics Placement: Pushing the Limits
Wuxi Biologics (Cayman) Inc (2269 HK) is a global one-stop biologics services provider and often referred to as CRO (contract research...
476 Views
Pharmaron (康龙化成) Post-IPO: A/H Convergence Post Connect Inclusion Supports A Trade
Pharmaron, the second-largest contract research organization (CRO) in China, was listed in Hong Kong on November 28th. The deal was anchored by a...
503 Views
Pharmaron Beijing: Trading Debut, Valuation Scenario Analysis
Pharmaron Beijing Co Ltd-H (3759 HK) is a global contract research organisation (CRO) and is one of the top three drug discovery service providers...
416 Views
Pharmaron (康龙化成) A+H: Allocation and Thoughts on Trading
Pharmaron, the second-largest contract research organization (CRO), raised USD 560 m at HKD 39.50/share. In this insight, we will cover the...
441 Views